Communiqués Novartis AG

Actions

NOVN

CH0012005267

Produits pharmaceutiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:06 12/05/2026			Varia. 5j.	Varia. 1 janv.
115,90 ^CHF	+1,93%		+2,08%	+5,75%

07:47	L'inflation plombe un peu l'ambiance
08/05	Bourse : Stellantis et Leapmotor vont plus loin, Monster flambe

Communiqués

11/05	Medicines, Monopolies, And Justice: India’s Fight For Fair Patents	AQ
07/05	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	GL
07/05	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	GL
05/05	Novartis : Earnings Document (novartis q1 2026 impact and sustainability update)	PU
30/04	Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility	GL
30/04	Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility	GL
28/04	Novartis: Q1 Earnings Snapshot	AQ
28/04	Novartis : Earnings Document (q1 2026 interim financial report en)	PU
28/04	Novartis : Earnings Document (q1 2026 investor presentation)	PU
28/04	Novartis : Earnings Document (novartis target patient populations 2026)	PU
28/04	Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed	GL
27/04	Novartis malaria treatment Coartem Baby receives WHO prequalification, paving way for greater access for newborns and young infants	AQ
27/04	Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria	GL
24/04	Novartis : withdraws EMA application for adding new indication for Pluvicto®	PU
24/04	Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)	GL
24/04	Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants	GL
24/04	Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants	GL
09/04	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030	GL
09/04	Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030	GL
30/03	Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%	AQ
30/03	Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation	AQ
29/03	Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%	GL
27/03	Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation	GL
23/03	Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline	AQ
23/03	Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026	GL